[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623255":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":46,"collaborators":23,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":23,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":23,"enrollmentInfo":58,"targetDuration":23,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":23,"overallStatus":36,"whyStopped":23,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Minia University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intrastromal moxifloxacin injection plus standard topical moxifloxacin therapy","EXPERIMENTAL","Intrastromal injection of preservative-free moxifloxacin 0.5% using a 30-gauge needle under aseptic conditions.",[13],"Drug: Intrastromal moxifloxacin injection plus standard topical moxifloxacin therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Standard topical moxifloxacin therapy alone","• Intensive topical moxifloxacin eye drops every 1-2 hours initially, tapered according to standard clinical protocol and response",[18],"Drug: Standard topical moxifloxacin therapy alone",[20,24],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":23},"DRUG",[9],null,{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":23},"Intensive topical moxifloxacin eye drops every 1-2 hours initially, tapered according to standard clinical protocol and response.",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":23,"email":32},"Mahmoud Ramadan Amer, MD","CONTACT","0201068005575","mahmoud3mer89@gmail.com",[34],{"facility":35,"status":36,"city":37,"state":23,"zip":23,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":23},"Mahmoud Ramadan Amer","RECRUITING","Minya","Egypt","EG",{"type":41,"coordinates":42},"Point",[43,44],30.75813,28.09193,{"lat":44,"lon":43},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Mahmoud Ramadan","lecturer of ophthalmology","100623255","intrastromal-moxifloxacin-as-an-adjunctive-therapy-in-recalcitrant-bacterial-keratitis-100623255",false,"NCT07394257","Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis","Inclusion Criteria:\n\n* • Age ≥ 18 years\n\n  * Clinical diagnosis of bacterial keratitis confirmed by corneal scraping and microbiology\n  * Recalcitrant keratitis defined as no significant clinical improvement after 48-72 hours of intensive topical antibiotic therapy\n  * Ability to provide written informed consent\n\nExclusion Criteria\n\n* Fungal, viral, or acanthamoeba keratitis\n* Corneal perforation or impending perforation\n* Known hypersensitivity to fluoroquinolones\n* Pregnancy or lactation\n* Immunocompromised state or current systemic immunosuppressive therapy\n* Previous intrastromal or intracameral antibiotic injection for the same episode","ALL","20 Years",{"count":59,"type":60},60,"ESTIMATED","INTERVENTIONAL",[63],"NA","Bacterial keratitis is a potentially sight-threatening corneal infection that is commonly treated with intensive topical antibiotics. Despite appropriate therapy, some cases show inadequate clinical response, particularly when the infection involves the deep corneal stroma. Limited penetration of topical antibiotics into deeper corneal layers may contribute to treatment failure in these recalcitrant cases.\n\nIntrastromal antibiotic injection is a targeted drug-delivery approach that allows high local antimicrobial concentrations directly at the site of infection. Moxifloxacin is a broad-spectrum fluoroquinolone with proven efficacy in bacterial keratitis and favorable corneal tissue penetration. However, evidence regarding the clinical benefit and safety of intrastromal moxifloxacin as an adjunctive treatment remains limited.\n\nThis randomized controlled trial aims to evaluate the efficacy and safety of intrastromal moxifloxacin injection as an adjunct to standard topical moxifloxacin therapy compared with topical therapy alone in patients with recalcitrant bacterial keratitis. The primary outcome is time to complete clinical resolution of infection. Secondary outcomes include visual acuity improvement, ulcer healing rate, need for additional interventions, and treatment-related complications.",[66,67,68],"Bacterial Keratitis","Recalcitrant Infectious Keratitis","Corneal Ulcer","2026-02-01",{"date":71,"type":72},"2026-02-06","ACTUAL",{"date":74,"type":72},"2025-10-01",{"date":76,"type":60},"2026-04-01",{"name":5,"class":6},1]